611 W. Union Street
Benson, AZ 85602
(520) 586-0800

member support line
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line


611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line


powered by centersite dot net
Basic InformationLatest News
Many Black Men Missed Out on Prostate Cancer Care During PandemicMixed Progress Against Cancers in Teens, Young AdultsBogus Info on Cancer Common Online, and It Can HarmScreening Often Misses Endometrial Cancer in Black WomenLong Distance to Care Can Mean Worse Outcomes for Young Cancer PatientsAlcohol Tied to 740,000 Cancer Cases Worldwide in 2020Cancer Survivors Fared Better Financially After ObamacarePandemic Delays in Screening Mean More Breast Cancer Deaths Ahead: StudyObese Men May Have Better Survival With Advanced Prostate CancerMost Cancer Screenings Make Big Rebound After Pandemic DeclineAdding MRI to Screening Can Cut Prostate Cancer Overdiagnosis in HalfU.S. Deaths From Cancer Continue to DeclineAlmost All Cancer Patients Respond Well to COVID-19 VaccinesCould Too Many Antibiotics Raise Your Odds for Colon Cancer?Too Little Sunlight, Vitamin D May Raise Colon Cancer RiskShining a Light on SunscreensGap in Breast Cancer Survival for Black, White Patients Shrinks, But Not by EnoughCost a Barrier to Cervical Cancer Screening for Many U.S. WomenMost Americans Don't Follow Diets That Could Prevent CancerAHA News: Women With Heart Failure From Breast Cancer Treatment May Fare Better Than Previously ThoughtWomen's Cancer Screenings Plummeted During PandemicYoung Cancer Survivors Vulnerable to COVID, But Often Shun VaccineSome Myeloma Patients Get No Protection From COVID-19 VaccinesBlack Men Less Likely to Get Best Prostate Cancer TreatmentsCould Home Test for Colon Cancer Mean a Big Medical Bill to Come?Heart Failure Patients May Be at Higher Cancer RiskCould a DNA Blood Test Spot a Range of Hidden Cancers?For People With Heart Failure, Statins May Lower Cancer Risk TooMany 'High-Risk' Americans Unconcerned About Skin Cancer: PollSurvivors' Plasma Helps Blood Cancer Patients Battle COVID-19Race Doesn't Affect Risk for Genes That Raise Breast Cancer RiskHealthy Levels of Vitamin D May Boost Breast Cancer OutcomesStudy Pinpoints Cancer Patients at Highest Risk From COVIDCan You Keep Your Bladder After Bladder Cancer Strikes?Breast Cancer's Spread Is More Likely in Black Women, Study FindsNewly Approved Drug Fights Lung Cancer Tied to Certain GenesDrug Lynparza Could Help Fight Some Early-Stage Breast CancersTargeted Radiotherapy Might Help Men Battling Advanced Prostate CancerOut-of-Pocket Costs Delay Cancer Follow-Up Care, Even for the InsuredDon't Delay Lung Cancer Surgery, Study SuggestsModerate Use of Hair Relaxers Won't Raise Black Women's Cancer Risk: StudyFaulty Gene Could Raise Vulnerability to Asbestos-Linked CancerColonoscopy After 75: A Potential Lifesaver for MostBreast Cancer Treatments Don't Raise COVID RisksImmunotherapy Drug Can Beat Back Early-Stage Lung CancerKey Factors That Raise Your Odds for Early-Onset Colon CancerHPV Vaccination Is Lowering U.S. Cervical Cancer RatesAs Medicaid Access Expands, So Does Cancer SurvivalMS May Not Affect Breast Cancer PrognosisGet First Colonoscopy at 45, not 50: U.S. Expert Panel
LinksBook ReviewsSelf-Help Groups
Related Topics

Medical Disorders
Pain Management

How the Pandemic Changed Breast Cancer Care

HealthDay News
by By Cara Murez HealthDay Reporter
Updated: May 4th 2021

new article illustration

TUESDAY, May 4, 2021 (HealthDay News) -- As the COVID-19 pandemic unfolded, breast cancer experts realized space in operating rooms and hospitals could become scarce. That meant rethinking standard care, to provide the best way to treat patients under these suddenly restricted conditions.

One of the new ideas: Reverse the order of care given to patients with a type of breast cancer known as estrogen receptor-positive (ER+). ER+ cancer is a common type of breast cancer and generally has a good outlook.

Instead of getting medication known as neoadjuvant endocrine therapy (NET) after surgery, as is more common, patients would receive NET first and surgery later, because ORs were so scarce. And because doctors didn't know how long the postponement in surgeries might last, they set up a system to track what was happening to women who affected by the delays across the United States.

Study leader Dr. Lee Wilke said her team wanted to "catalog across the country how long did patients get their surgery postponed or their treatment postponed, and what mechanisms did surgeons use to try and make sure that they were still able to treat their patients in an effective manner." Wilke is professor of surgery at University of Wisconsin School of Medicine and Public Health, in Madison.

The preliminary findings were presented Sunday at an online meeting of the American Society of Breast Surgeons (ASBrS). Research presented at meetings is typically considered preliminary until published in a peer-reviewed journal.

Treating cancers in this way was part of an effort by the breast surgeons' group and other cancer societies to develop treatment guidelines for times when access to operating rooms is limited.

Doctors also developed a series of options to further evaluate patients, Wilke said. This included testing for gene mutations in a tumor's DNA to determine which patients needed chemotherapy.

Patients who needed standard approaches still got them, Wilke said. For example, women with aggressive triple negative and HER2+ tumors were still treated with chemotherapy.

Data used in the study came from nearly 4,800 patients listed in the registry starting in March 2020. In all, 172 breast surgeons entered information in the registry.

Due to COVID-19, NET was used to treat an additional 554 patients (36%) who would otherwise have had surgery first between March 1 and Oct. 28, 2020, the study found. Later results through March 2021 put the total at 31%.

NET was also used in 6.5% to 7.8% of patients in the registries who would typically have had this treatment, the study authors said in an ASBrS news release.

The patterns found in the registry are what cancer experts discussed early in the pandemic, said Dr. Tari King, chief of breast surgery at Dana-Farber/Brigham and Women's Cancer Center in Boston, who was not involved in the study.

"We had good data to support that this would be a reasonable strategy for the majority of patients coming in with ER+ breast cancer, that we could use this as a bridge to surgery without negatively impacting their outcomes," King said.

Several clinical trials had already validated the approach, which is more common in Europe.

Anti-estrogen endocrine therapy blocks or decreases the ability of hormones to grow certain types of cancer cells. In the United States, it is typically used in postmenopausal women with larger tumors, Wilke said.

The study also found that there were fewer immediate breast reconstruction surgeries because shorter operating times prioritized cancer removal.

About 24% of patients had testing for genetic mutations on biopsied tumor tissue, the study found.

Dana-Farber/Brigham and Women's Cancer Center was already using core biopsy for these genomic studies to determine which women needed chemotherapy prior to surgery, King said.

In places like Boston, cancer treatment returned to normal in the late fall, she noted.

King said many of the patients who started on preoperative endocrine therapy at the center didn't stay on the treatment as long as they normally would have if the goal had been to shrink the tumor, because they were already candidates for a lumpectomy.

Though this treatment change was temporary, King said it challenges researchers to think more broadly about which patients may benefit from NET in the future. It shrinks tumors as well as chemo, but it takes longer to do so, she said.

"But certainly neoadjuvant endocrine therapy has far fewer side effects, far less toxicity than chemotherapy does," King said. "I think it does push us to think about using it more broadly when we're trying to shrink an ER+ tumor if the patient is otherwise not a candidate for chemotherapy."

Wilke added that it may take three to five years to understand the full impact of the changes stemming from the pandemic. Some of the new protocols may continue.

More information

The American Cancer Society has more about breast cancer.

SOURCES: Lee Wilke, MD, professor, surgery, University of Wisconsin School of Medicine and Public Health, and director, UW Health Breast Center, Madison; Tari King, MD, chief, breast surgery, Dana-Farber/Brigham and Women's Cancer Center, professor, surgery, Harvard Medical School, and associate chairwoman, multidisciplinary oncology, Brigham and Women's Hospital, Boston; American Society of Breast Surgeons, annual meeting, May 2, 2021, online presentation